Case Study: Switching to Adalimumab Biosimilar for Ulcerative Colitis Table of Contents Case Study: Switching to Adalimumab Biosimilar for Ulcerative Colitis Clinical Presentation and Treatment Plan Implications for U.S. Patients Areas for Further Investigation Adalimumab Biosimilars in the U.S. Market Case Study: Switching to Adalimumab biosimilar for Ulcerative Colitis Key Questions and Answers What is … Read more
Image credit: EVGENIA – stock.adobe.com Physicians and researchers from Saga University Hospital in Japan described a case of a 15-year-old girl with ulcerative colitis (UC) who switched from the adalimumab reference product to the biosimilar LBAL (LG Chem) after the eighth adalimumab dose when injection site reactions had begun to develop. The biosimilar was continued … Read more
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman’s disease (iMCD). This rare disease has an especially poor survival rate and few treatment options. The patient could be the first of many to have their lives saved by an AI … Read more